Study on heart function drugs for liver cirrhosis patients
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests two heart medications, carvedilol and empagliflozin, to see if they improve heart function in people with cirrhosis (liver scarring). It might help those who have early signs of heart stiffness but normal pumping strength.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with cirrhosis (liver scarring) through a biopsy, blood tests, or ultrasound.
- Your heart has mild stiffness (LVDD) but still pumps blood normally (EF over 50%), confirmed by an echocardiogram.
- You have not had a urinary or genital infection in the last 3 months.
- You are not currently taking statin drugs, and your kidney function is good (creatinine under 2 mg/dl).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a statin (simvastatin) to the usual heart medication carvedilol helps people with both cirrhosis and a related heart problem live longer and avoid serious liver complications.
This Phase 2 study tests empagliflozin to see if it can improve fluid buildup (ascites) in people with cirrhosis. It may help reduce symptoms related to fluid retention, but you must meet specific safety and stability requirements.
This trial tests whether adding metformin to carvedilol (a standard drug) lowers liver pressure more than carvedilol alone in people with cirrhosis who have had variceal bleeding. The goal is to prevent future bleeding.
This trial tests if the drug carvedilol can prevent liver-related emergencies or death in people with cirrhosis and high blood pressure in the liver. It may help those who are stable right now but at risk for a sudden worsening.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
This trial tests if a diabetes medicine called empagliflozin can help people with Fontan circulatory failure feel better and do more of their daily activities.
Hear when a new Cirrhotic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.